Antigen presentation defects in tumors are prevalent mechanisms of adaptive immune
evasion and resistance to cancer immunotherapy, whereas how tumors evade innate …

Immune checkpoints modulate the immune response and represent important
immunotherapy targets for cancer treatment. However, as many tumors are resistant to …

Glioma is the most prevalent primary brain tumor. Immune checkpoint blockade has made a
great stride in mending patient's clinical outcome for multiple types of cancers. However, PD …

Immunotherapy options for patients with cancer have emerged following decades of
research on immune responses against tumors. Most treatments in this category harness T …

Natural Killer (NK) cells control metastatic dissemination of murine tumors and are an
important prognostic factor in several human malignancies. However, tumor cells hijack …

Tumor antigen-specific CD8+ T cells play a critical role in antitumor immunity. Clinical trials
reinvigorating the immune system via immune checkpoint blockade (ICB) have shown …

Current methods for biomarker discovery and target identification in immuno-oncology rely
on static snapshots of tumor immunity. To thoroughly characterize the temporal nature of …

Tumor escape mechanisms for immunotherapy include deficiencies in antigen presentation,
diminishing adaptive CD8+ T cell antitumor activity. Although innate natural killer (NK) cells …

Background Patients with hepatocellular carcinoma (HCC) suffer from a high fatality rate,
likely due to increased incidence of tumor relapse and metastasis. Understanding the …

Checkpoint blockade therapy, for example using antibodies against CTLA-4 and PD-1/PD-
L1, relieves T cells from the suppression by inhibitory checkpoints in the tumor …